Insmed's (INSM) "Buy" Rating Reaffirmed at HC Wainwright

Insmed (NASDAQ:INSM - Get Free Report)'s stock had its "buy" rating reissued by equities researchers at HC Wainwright in a note issued to investors on Monday,Benzinga reports. They presently have a $90.00 price objective on the biopharmaceutical company's stock. HC Wainwright's price objective suggests a potential upside of 38.29% from the company's current price.

Several other research firms have also issued reports on INSM. Bank of America increased their target price on Insmed from $92.00 to $96.00 and gave the stock a "buy" rating in a report on Thursday, March 20th. Stifel Nicolaus dropped their target price on Insmed from $97.00 to $96.00 and set a "buy" rating for the company in a research report on Friday, February 21st. Royal Bank of Canada restated an "outperform" rating and set a $100.00 price objective on shares of Insmed in a research report on Wednesday, March 19th. JPMorgan Chase & Co. raised their price objective on Insmed from $83.00 to $92.00 and gave the stock an "overweight" rating in a research report on Friday, February 7th. Finally, Guggenheim reaffirmed a "buy" rating and set a $101.00 target price on shares of Insmed in a research note on Tuesday, February 25th. One analyst has rated the stock with a sell rating and sixteen have issued a buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average target price of $93.93.

Insmed Price Performance

Insmed stock opened at $65.08 on Monday. Insmed has a 1 year low of $21.92 and a 1 year high of $84.91. The company has a current ratio of 6.37, a quick ratio of 5.99 and a debt-to-equity ratio of 2.03. The firm has a market capitalization of $11.83 billion, a P/E ratio of -11.64 and a beta of 0.84. The business has a 50-day moving average of $72.37 and a 200-day moving average of $73.28.

Insmed (NASDAQ:INSM - Get Free Report) last announced its quarterly earnings data on Thursday, May 8th. The biopharmaceutical company reported ($1.42) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.36) by ($0.06). Insmed had a negative return on equity of 4,773.73% and a negative net margin of 251.24%. The company had revenue of $92.82 million for the quarter, compared to the consensus estimate of $91.63 million. During the same quarter in the prior year, the company earned ($1.06) EPS. The company's revenue for the quarter was up 22.9% on a year-over-year basis. On average, equities analysts anticipate that Insmed will post -4.56 EPS for the current year.

Insider Buying and Selling

In other Insmed news, CEO William Lewis sold 6,830 shares of the business's stock in a transaction that occurred on Tuesday, April 15th. The stock was sold at an average price of $70.16, for a total transaction of $479,192.80. Following the sale, the chief executive officer now directly owns 233,924 shares of the company's stock, valued at $16,412,107.84. The trade was a 2.84% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, CFO Sara Bonstein sold 13,302 shares of the company's stock in a transaction that occurred on Tuesday, February 11th. The shares were sold at an average price of $80.00, for a total value of $1,064,160.00. Following the transaction, the chief financial officer now directly owns 142,204 shares in the company, valued at approximately $11,376,320. This represents a 8.55% decrease in their position. The disclosure for this sale can be found here. Insiders sold 101,534 shares of company stock valued at $7,932,633 over the last 90 days. Company insiders own 3.00% of the company's stock.

Institutional Trading of Insmed

Hedge funds have recently bought and sold shares of the stock. Cullen Frost Bankers Inc. lifted its holdings in Insmed by 164.9% during the first quarter. Cullen Frost Bankers Inc. now owns 355 shares of the biopharmaceutical company's stock worth $27,000 after buying an additional 221 shares during the period. Elequin Capital LP acquired a new stake in Insmed during the 4th quarter worth about $28,000. Steward Partners Investment Advisory LLC grew its position in Insmed by 65.2% during the 4th quarter. Steward Partners Investment Advisory LLC now owns 413 shares of the biopharmaceutical company's stock worth $29,000 after purchasing an additional 163 shares during the period. V Square Quantitative Management LLC grew its position in shares of Insmed by 60.3% during the 4th quarter. V Square Quantitative Management LLC now owns 659 shares of the biopharmaceutical company's stock valued at $45,000 after acquiring an additional 248 shares during the period. Finally, Spire Wealth Management acquired a new stake in shares of Insmed during the 4th quarter valued at about $47,000.

Insmed Company Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.